Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{199925,
        author = {Akanksha Mehra and Arpan Das and Survi Barnawal and K. Hamsika Sri and Sakshi Bhosale and Rohit Dashrath Babar and Prajakta Chandrakant Patil},
        title = {3D Printing Technologies for Personalised Pharmaceutical Dosage Forms: Advances, Opportunities and Regulatory Challenges},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {12},
        pages = {880-899},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=199925},
        abstract = {The emergence of three-dimensional (3D) printing technologies has fundamentally transformed the landscape of pharmaceutical manufacturing, offering unprecedented opportunities for the fabrication of personalised dosage forms tailored to individual patient needs. This comprehensive review examines the current state of 3D printing in pharmaceutical sciences, encompassing a wide spectrum of technologies including fused deposition modelling (FDM), stereolithography (SLA), selective laser sintering (SLS), inkjet-based printing, and binder jetting. We critically evaluate the scientific advances enabling dose customisation, complex release kinetics, polypill fabrication, and patient-specific geometries. Furthermore, this review explores clinical opportunities for precision medicine in paediatric, geriatric, and oncology settings. The regulatory landscape is analysed with reference to frameworks from the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and international guidance bodies. Key challenges including material validation, Good Manufacturing Practice (GMP) compliance, quality control, intellectual property considerations, and scalability are discussed in depth. The integration of artificial intelligence (AI), digital pharmacies, point-of-care manufacturing, and bioprinting as emerging frontiers is also explored. This review identifies critical knowledge gaps and provides a forward-looking perspective on the path from bench to bedside for 3D-printed pharmaceuticals. [1,2,3]},
        keywords = {3D printing; additive manufacturing; personalised medicine; pharmaceutical dosage forms; FDM; SLA; SLS; inkjet printing; FDA; EMA; regulatory compliance; polypill; sustained release; point-of-care manufacturing.},
        month = {May},
        }